Revised SPC: Praxbind (idarucizumab) 2.5 g/50 mL solution for injection/infusion

Section 5.1 has been updated with information on a paediatric patient (between 16-<18 years old) treated with idarucizumab during an open-label safety trial.

Source:

electronic Medicines compendium